NCT05481073 is a clinical trial of UV sensor in Keratosis, Actinic, sponsored by Almirall, S.A..

Who is sponsoring NCT05481073?

NCT05481073 is sponsored by Almirall, S.A..

What drugs are being tested in NCT05481073?

Interventions in NCT05481073: UV sensor.

What condition does NCT05481073 study?

NCT05481073 studies Keratosis, Actinic.

Is NCT05481073 still recruiting?

NCT05481073 is currently completed. Last updated 14 November 2022.

Last reviewed 2022-11-14 · How we verify

NCT05481073

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UV Sensor in Patients With Actinic Keratosis

Completed Last updated 14 November 2022

What this trial tests

trial testing UV sensor in Keratosis, Actinic in 10 participants. Completed in 1 September 2022.

Timeline

13 June 2022

Primary endpoint
2 August 2022

1 September 2022

Quick facts

Lead sponsor	Almirall, S.A.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	13 June 2022
Primary completion	2 August 2022
Estimated completion	1 September 2022
Sites	1 location across Spain

Drugs / interventions tested

UV sensor

Conditions studied

Keratosis, Actinic — all drugs for Keratosis, Actinic →

Sponsor

Almirall, S.A. — full company profile →

Who can join

65 and older, any sex, with Keratosis, Actinic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To validate the use of Ultraviolet (UV) radiation sensor in patients with actinic keratosis, to identify barriers to its use in prospective longitudinal studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Keratosis, Actinic

Currently open trials in the same condition.

NCT05636800 — Microwave Treatment for Actinic Keratosis · NA · active not recruiting

Other Almirall, S.A. trials

Trials by the same sponsor.

NCT07471932 — A Study of LAD106 in Healthy Adult Participants · Phase 1 · recruiting
NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
NCT06135415 — A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis · Phase 3 · completed
NCT06200597 — A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects · Phase 1 · completed
NCT05990725 — Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05481073 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Almirall, S.A.
Last refreshed: 14 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing